CS has provided scientific advisory for SwanBio/Spur Therapeutics and his institution has received research funding from Sanofi-Genzyme for a study of video oculography in late-onset GM2 gangliosidosis. He has received financial support from SwanBio/Spur Therapeutics, Encora Therapeutics, Sanofi-Genzyme, Biogen, and Biohaven for the conduct of clinical trials. He has received honoraria from the International Parkinson and Movement Disorders Society, the American Academy of Neurology/Continuum and Oakstone CME for the production of educational material. He has received grant support from the National Institutes of Health K23 NS118045. CA has received speaker honoraria from Abbvie, Bial, Zambon, Lusofarmaco, Ralpharma. FP joined Janssen Pharmaceutical Companies of Johnson and Johnson in October 2022. MM is supported by the National Institutes of Health, R01 HD100383, R01 HD107074, R01 AG077380, R01 HD110389, U01 NS113851, and the Michael J Fox Foundation for Research, MJFF-024177, and MJFF-024692. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.